NEW YORK, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced that the Company will present at the following conferences:
1. Morgan Stanley Global Healthcare Unplugged Conference, held at the
Grand Hyatt in New York on September 9, 2008;
2. Merrill Lynch Global Pharmaceutical Conference, held at the Merrill
Lynch Financial Centre in London on September 17, 2008;
3. UBS Global Life Sciences Conference, held at the Grand Hyatt in New
York on September 25, 2008. To access the webcast of this event,
please go to http://www.ibb.ubs.com/ .
Management will also hold one-on-one meetings at the conferences. For more details on the aforementioned conferences, please visit the respective conference organizers websites.
About American Oriental Bioengineering Inc.
American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China.
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company’s filings with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
